Last 12 months
Inside the activity.
0 purchase rows · 19 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 5 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2020 Filed Sep 11, 2020 20:12 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 7,030 | $56.96 | $400,428.80 |
DisclosureSEC source: 0001127602-20-024981 · form4.xml · nonDerivative · entry 4 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,119,683 F6 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019. F7 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 20:12 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 10,000 | $56.96 | $569,600.00 |
DisclosureSEC source: 0001127602-20-024981 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,764,880 F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on May 21, 2020. F5 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 20:12 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
GiftCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-024981 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,673,868 F2 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020. F3 · price: The reported disposition represents a bona fide charitable gift made by the reporting person. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 20:12 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 9,000 | $55.81 | $502,290.00 |
DisclosureSEC source: 0001127602-20-024981 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,674,868 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:50 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-024906 · form4.xml · derivative · entry 12 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,790 Underlying: Common Stock · 10,000 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F8 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:50 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $14.22 | $0.00 |
DisclosureSEC source: 0001127602-20-024906 · form4.xml · derivative · entry 11 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,243 Underlying: Common Stock · 5,000 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F7 · derivative.exercise_date: 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:50 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,467 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-024906 · form4.xml · derivative · entry 10 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,945 Underlying: Common Stock · 1,467 shares Expires 2027-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F6 · derivative.exercise_date: 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:50 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-20-024906 · form4.xml · derivative · entry 9 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,195 Underlying: Common Stock · 10,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:50 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 4,960 | $57.88 | $287,084.80 |
DisclosureSEC source: 0001127602-20-024906 · form4.xml · nonDerivative · entry 8 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.39 to $58.28. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:50 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 6,457 | $56.82 | $366,886.74 |
DisclosureSEC source: 0001127602-20-024906 · form4.xml · nonDerivative · entry 7 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,960 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.37 to $57.31. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:50 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 8,655 | $55.88 | $483,641.40 |
DisclosureSEC source: 0001127602-20-024906 · form4.xml · nonDerivative · entry 6 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,417 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.36 to $56.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:50 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 6,395 | $54.69 | $349,742.55 |
DisclosureSEC source: 0001127602-20-024906 · form4.xml · nonDerivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,072 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.30 to $55.23. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:50 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 10,000 | $19.15 | $191,500.00 |
DisclosureSEC source: 0001127602-20-024906 · form4.xml · nonDerivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:50 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 5,000 | $14.22 | $71,100.00 |
DisclosureSEC source: 0001127602-20-024906 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:50 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 1,467 | $12.21 | $17,912.07 |
DisclosureSEC source: 0001127602-20-024906 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:50 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 10,000 | $20.93 | $209,300.00 |
DisclosureSEC source: 0001127602-20-024906 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| September 04, 2020 Filed Sep 8, 2020 21:06 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 1,000 | $64.18 | $64,180.00 |
DisclosureSEC source: 0001127602-20-024789 · form4.xml · nonDerivative · entry 5 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 419,764 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.90 to $64.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| September 04, 2020 Filed Sep 8, 2020 21:06 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 2,236 | $62.91 | $140,666.76 |
DisclosureSEC source: 0001127602-20-024789 · form4.xml · nonDerivative · entry 4 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 420,764 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.56 to $63.46. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| September 04, 2020 Filed Sep 8, 2020 21:06 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 3,350 | $62.02 | $207,767.00 |
DisclosureSEC source: 0001127602-20-024789 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 423,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.55 to $62.52. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| September 04, 2020 Filed Sep 8, 2020 21:06 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 3,760 | $60.96 | $229,209.60 |
DisclosureSEC source: 0001127602-20-024789 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 426,350 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.50 to $61.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| September 04, 2020 Filed Sep 8, 2020 21:06 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 700 | $59.48 | $41,636.00 |
DisclosureSEC source: 0001127602-20-024789 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 430,110 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.24 to $60.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| September 03, 2020 Filed Sep 4, 2020 20:31 UTC |
Hoge StephenPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001127602-20-024766 · form4.xml · derivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 817,431 Underlying: Common Stock · 10,000 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| September 03, 2020 Filed Sep 4, 2020 20:31 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 10,000 | $65.65 | $656,500.00 |
DisclosureSEC source: 0001127602-20-024766 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,946,530 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. Read SEC document |
| September 03, 2020 Filed Sep 4, 2020 20:31 UTC |
Hoge StephenPresident
|
Exercise / conversionCommon Stock | 10,000 | $0.99 | $9,900.00 |
DisclosureSEC source: 0001127602-20-024766 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,956,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. Read SEC document |
| September 03, 2020 Filed Sep 4, 2020 20:28 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 10,000 | $65.65 | $656,500.00 |
DisclosureSEC source: 0001127602-20-024764 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,774,880 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on May 21, 2020. F2 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 20:24 UTC |
Hoge StephenPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001127602-20-024704 · form4.xml · derivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827,431 Underlying: Common Stock · 10,000 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 20:24 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 10,000 | $62.89 | $628,900.00 |
DisclosureSEC source: 0001127602-20-024704 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,946,530 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 20:24 UTC |
Hoge StephenPresident
|
Exercise / conversionCommon Stock | 10,000 | $0.99 | $9,900.00 |
DisclosureSEC source: 0001127602-20-024704 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,956,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 20:16 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
GiftCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-024700 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,683,868 F4 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020. F5 · price: The reported disposition represents a bona fide charitable gift made by the reporting person. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 20:16 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 9,000 | $62.89 | $566,010.00 |
DisclosureSEC source: 0001127602-20-024700 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,684,868 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:16 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 9,247 | $63.54 | $587,554.38 |
DisclosureSEC source: 0001127602-20-024700 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,126,713 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019. F2 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 20:18 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-024563 · form4.xml · derivative · entry 12 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,790 Underlying: Common Stock · 10,000 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F8 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 20:18 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $14.22 | $0.00 |
DisclosureSEC source: 0001127602-20-024563 · form4.xml · derivative · entry 11 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,243 Underlying: Common Stock · 5,000 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F7 · derivative.exercise_date: 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 20:18 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-024563 · form4.xml · derivative · entry 10 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,412 Underlying: Common Stock · 5,000 shares Expires 2027-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F6 · derivative.exercise_date: 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 20:18 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-20-024563 · form4.xml · derivative · entry 9 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,195 Underlying: Common Stock · 10,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 20:18 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 1,823 | $66.52 | $121,265.96 |
DisclosureSEC source: 0001127602-20-024563 · form4.xml · nonDerivative · entry 8 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.19 to $67.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 20:18 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 4,807 | $64.81 | $311,541.67 |
DisclosureSEC source: 0001127602-20-024563 · form4.xml · nonDerivative · entry 7 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,823 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.58 to $65.55. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 20:18 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 14,700 | $64.16 | $943,152.00 |
DisclosureSEC source: 0001127602-20-024563 · form4.xml · nonDerivative · entry 6 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,630 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.57 to $64.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 20:18 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 8,670 | $63.09 | $546,990.30 |
DisclosureSEC source: 0001127602-20-024563 · form4.xml · nonDerivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,330 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.56 to $63.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 20:18 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 10,000 | $19.15 | $191,500.00 |
DisclosureSEC source: 0001127602-20-024563 · form4.xml · nonDerivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 20:18 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 5,000 | $14.22 | $71,100.00 |
DisclosureSEC source: 0001127602-20-024563 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 20:18 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0001127602-20-024563 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 20:18 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 10,000 | $20.93 | $209,300.00 |
DisclosureSEC source: 0001127602-20-024563 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 28, 2020 Filed Sep 1, 2020 20:12 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 802 | $67.83 | $54,399.66 |
DisclosureSEC source: 0001127602-20-024560 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 430,810 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.73 to $67.99. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| August 28, 2020 Filed Sep 1, 2020 20:12 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 4,275 | $67.17 | $287,151.75 |
DisclosureSEC source: 0001127602-20-024560 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 431,612 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.71 to $67.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| August 28, 2020 Filed Sep 1, 2020 20:12 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 5,969 | $66.19 | $395,088.11 |
DisclosureSEC source: 0001127602-20-024560 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 435,887 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.67 to $66.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| August 27, 2020 Filed Aug 28, 2020 21:01 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 10,000 | $69.91 | $699,100.00 |
DisclosureSEC source: 0001127602-20-024402 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,784,880 F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on May 21, 2020. F5 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| August 26, 2020 Filed Aug 28, 2020 21:01 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
GiftCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-024402 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,693,868 F2 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020. F3 · price: The reported disposition represents a bona fide charitable gift made by the reporting person. Read SEC document |
| August 26, 2020 Filed Aug 28, 2020 21:01 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 9,000 | $67.45 | $607,050.00 |
DisclosureSEC source: 0001127602-20-024402 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,694,868 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:55 UTC |
Hoge StephenPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001127602-20-024227 · form4.xml · derivative · entry 8 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 837,431 Underlying: Common Stock · 10,000 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F7 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.